HC dismisses PIL on vaccine trials

Image
Press Trust of India New Delhi
Last Updated : Oct 14 2015 | 3:57 PM IST
The Delhi High Court today dismissed a plea seeking a direction to restrain the Centre from conducting any further clinical trials of rotavirus vaccine in India, saying the petition "does not deserve to be taken cognizance as a Public Interest Litigation".
Rotavirus vaccine protects children from viruses, which are the leading cause of severe diarrhoea among infants and young children.
A bench of Chief Justice G Rohini and Justice Jayant Nath said no case of violation of any statutory provision is made out in the present petition and no case is also made out to show that disclosure of the segregated data of clinical trial is essential in public interest.
"We, therefore, find substance in the submission of the Additional Solicitor General (ASG) that the petition is misconceived and motivated with private interest. For the aforesaid reasons, the petition does not deserve to be taken cognizance as a Public Interest Litigation," the bench said.
The court's order came on a plea filed by Dr Jacob Puliyel, a member of National Technical Advisory Group on Immunization (NTAGI) seeking to restrain the government from moving on to phase IV trials in which over one lakh children would be administered the vaccine.
Puliyel in his plea has also sought directions to the government to provide complete data of the multi-centre clinical trials of the vaccine.
The bench said NTAGI, which is the highest technical advisory body in the country on immunizationon on being satisfied about its efficacy and safety, has recommended to introduce the vaccine in question for National Immunization Programme.
"In the circumstances, we do not find any substance in the contention of the petitioner that in the absence of the information about the number of cases of intussusceptions in clinical trial at one of the centres, the Government cannot be allowed to proceed to take up Phase-IV study of the vaccine," the bench said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 14 2015 | 3:57 PM IST

Next Story